- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.05. | Virogates A/S Q1 Loss Drops | - | RTTNews | ||
| 07.05. | ViroGates A/S: ViroGates announces its Interim Report for Q1-2026 | 174 | GlobeNewswire (Europe) | Company Announcement no. 5/2026 (May 07, 2026 at 13:12:00 CEST)
Revenue increased 8% Y-o-Y in Q1 to DKK 1.3 million, and net loss decreased by 6% to DKK 2.6 million
BIRKERØD, DENMARK - ViroGates A/S... ► Artikel lesen | |
| 23.04. | ViroGates A/S: Resolutions from the Annual General Meeting of ViroGates A/S | 152 | GlobeNewswire (Europe) | Company Announcement no. 4/2026 (April 23, 2026 at 20:15:00 CEST)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring... ► Artikel lesen | |
| 08.04. | ViroGates A/S: ViroGates submits its De Novo application to the U.S. FDA for suPARnostic TurbiLatex | 338 | GlobeNewswire (Europe) | Company Announcement no. 3/2026 (April 08, 2026 at 22:37:00 CEST)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 26.03. | ViroGates A/S: ViroGates announces its Annual Report 2025: Revenue growth and improved operating result as strategic transition towards preventive health and longevity continues | 735 | GlobeNewswire (Europe) | Company Announcement no. 1/2026 (March 26, 2026 at 15:10:00 CET)
Inside information
BIRKERØD, DENMARK ViroGates A/S ("ViroGates" or "Company"), a medical technology company developing blood tests for... ► Artikel lesen | |
| VIROGATES Aktie jetzt für 0€ handeln | |||||
| 12.12.25 | ViroGates A/S: ViroGates announces financial guidance for 2026 | 226 | GlobeNewswire (Europe) | Company Announcement no. 22/2025 (December 12, 2025)
BIRKERØD, DENMARK-ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 28.11.25 | ViroGates A/S: ViroGates' capital raise of DKK 19.3 million and issue of 1,547,412 shares have been registered and settled | 409 | GlobeNewswire (Europe) | Company Announcement no. 21/2025 (November 28, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company") announces that the capital raise of approximately DKK 19.3 million and the issue... ► Artikel lesen | |
| 26.11.25 | ViroGates A/S - increase | 266 | GlobeNewswire | New shares in ViroGates A/S will be admitted to trading on Nasdaq First North Growth Market Denmark as of 28 November 2025. New shares are issued due to a directed issue of new shares.
Name:
ViroGates
ISIN:
DK0061030574
Short... ► Artikel lesen | |
| 12.11.25 | ViroGates A/S - Observation status | 248 | GlobeNewswire | Nasdaq Copenhagen has today removed observation status for:
ISIN NAME
DK0061030574 VIROGATES
The company's observation status has been removed... ► Artikel lesen | |
| 12.11.25 | ViroGates A/S: suPAR Remedy, LLC announces the outcome of the Public Tender Offer to the shareholders of ViroGates | 265 | GlobeNewswire (Europe) | Company Announcement no. 17/2025 (November 12, 2025)
BIRKERØD, DENMARK - Today, suPAR Remedy, LLC (the "Offeror") announces the outcome of the public tender offer published on 8 October 2025 and on... ► Artikel lesen | |
| 06.11.25 | ViroGates A/S: ViroGates announces its Interim Report for Q1-Q3 2025 | 237 | GlobeNewswire (Europe) | Company Announcement no. 16/2025 (November 06, 2025)
Revenue rose 49% Y-o-Y in Q3, and total revenue for the first nine months is now slightly above the same period in 2024
BIRKERØD, DENMARK - ViroGates... ► Artikel lesen | |
| 08.10.25 | ViroGates A/S - Observation status | 294 | GlobeNewswire | Nasdaq Copenhagen has given the company below observation status:
ISIN DK0061030574 Symbol VIRO
ViroGates A/S has been given observation status, as the company has announced that suPAR... ► Artikel lesen | |
| 08.10.25 | ViroGates A/S: suPAR Remedy, LLC announces public tender offer to the shareholders of ViroGates A/S at a 40% premium | 336 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Company... ► Artikel lesen | |
| 21.08.25 | ViroGates A/S: ViroGates announces its Half-Year Report for H1 2025 | 245 | GlobeNewswire (Europe) | Company Announcement no. 10/2025 (August 21, 2025)
Revenue ending 18% below H1 2024, operating loss reduced by 26%, and proof of concept achieved for suPARnostic® POC+ in longevity
BIRKERØD, DENMARK... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 133,57 | 0,00 % | AbbVie-Aktie: Apogee-Übernahme beflügelt | Die AbbVie-Aktie hat den Wegfall des einstigen Blockbusters Humira deutlich besser verkraftet als viele Anleger erwartet hatten. Mit der milliardenschweren Übernahme von Apogee Therapeutics will der... ► Artikel lesen | |
| QIAGEN | 36,670 | +10,62 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| ERASCA | 19,180 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RELAY THERAPEUTICS | 20,750 | 0,00 % | JPMorgan stuft Relay Therapeutics zum Start mit "Overweight" ein | ||
| VIRAX BIOLABS GROUP | 6,340 | -0,31 % | Morning Market Movers: Virax Biolabs, Aimei Health Technology, Sadot Group, Ionis Pharmaceuticals See Big Swings | BEIJING (dpa-AFX) - At 8:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COGENT BIOSCIENCES | 40,470 | -0,10 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 64,15 | +0,02 % | Tarsus Acquires iRenix Medical To Expand Eye Care Pipeline With Late-Stage IRX-101 | ||
| ENLIVEN THERAPEUTICS | 52,18 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| BEAM THERAPEUTICS | 35,840 | +0,06 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| VERA THERAPEUTICS | 42,420 | -0,07 % | Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner | BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer... ► Artikel lesen | |
| ABSCI | 11,465 | -0,04 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VOR BIOPHARMA | 19,750 | 0,00 % | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 48,380 | +0,06 % | Oppenheimer initiates Edgewise Therapeutics stock with outperform rating | ||
| TYRA BIOSCIENCES | 33,010 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| TANGO THERAPEUTICS | 30,520 | 0,00 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen |
VIROGATES A/S gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIROGATES A/S finden Sie auf Wallstreet Online.